Systemic Anti-Inflammatory Agents in the Prevention of Chemoradiation-Induced Mucositis: A Review of Randomised Controlled Trials

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 May 24

PMID 38785967

Authors

Ali I Mohammed

Lexi Fedoruk

Nicholas Fisher

Andy Xiaoqian Liu

Samar Khanna

Kaelan Naylor

Ziyi Gong

Antonio Celentano

Mohammad S Alrashdan

Nicola Cirillo

Affiliations

Soon will be listed here.

Abstract

Mucositis is a pathological condition characterised by inflammation and ulceration of the mucous membranes lining the alimentary canal, particularly in the mouth (oral mucositis) and the gastrointestinal tract. It is a common side effect of cancer treatments, including chemotherapy and radiotherapy, and it is sometimes responsible for treatment interruptions. Preventing mucositis throughout the alimentary tract is therefore crucial. However, current interventions mainly target either oral or gastrointestinal side effects. This review aimed to investigate the use of systemically administered anti-inflammatory agents to prevent mucositis in cancer patients undergoing cancer treatment. PubMed, Ovid, Scopus, Web of Science, WHO ICTRP and ClinicalTrials.gov were screened to identify eligible randomised controlled trials (RCTs). The published literature on anti-inflammatory agents provides mixed evidence regarding the degree of efficacy in preventing/reducing the severity of mucositis in most anticancer treatments; however, sample size continued to be a significant limitation, alongside others discussed. Our review yielded a list of several anti-inflammatory agents that exhibit potential mucositis-preventive effects in cancer patients undergoing cancer treatment, which can be used to inform clinical practice.

References

Ihle J . The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001; 13(2):211-7. DOI: 10.1016/s0955-0674(00)00199-x. View

Lalla R, Peterson D . Oral mucositis. Dent Clin North Am. 2004; 49(1):167-84, ix. DOI: 10.1016/j.cden.2004.07.009. View

Kazemian A, Kamian S, Aghili M, Hashemi F, Haddad P . Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl). 2009; 18(2):174-8. DOI: 10.1111/j.1365-2354.2008.00943.x. View

Rhoads J, Wu G . Glutamine, arginine, and leucine signaling in the intestine. Amino Acids. 2009; 37(1):111-22. DOI: 10.1007/s00726-008-0225-4. View

Ertekin M, Koc M, Karslioglu I, Sezen O . Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys. 2003; 58(1):167-74. DOI: 10.1016/s0360-3016(03)01562-1. View

LEBORGNE J, LEBORGNE F, Zubizarreta E, Ortega B, MEZZERA J . Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol. 1998; 47(2):145-8. DOI: 10.1016/s0167-8140(97)00174-6. View

Manna S, Mukhopadhyay A, Van N, Aggarwal B . Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999; 163(12):6800-9. View

Pahlavani N, Malekahmadi M, Firouzi S, Rostami D, Sedaghat A, Bagheri Moghaddam A . Molecular and cellular mechanisms of the effects of Propolis in inflammation, oxidative stress and glycemic control in chronic diseases. Nutr Metab (Lond). 2020; 17:65. PMC: 7425411. DOI: 10.1186/s12986-020-00485-5. View

Sonis S . Oral mucositis in cancer therapy. J Support Oncol. 2004; 2(6 Suppl 3):3-8. View

10.

Pulito C, Cristaudo A, La Porta C, Zapperi S, Blandino G, Morrone A . Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020; 39(1):210. PMC: 7542970. DOI: 10.1186/s13046-020-01715-7. View

11.

Javadzadeh Bolouri A, Pakfetrat A, Tonkaboni A, Aledavood S, Najafi M, Delavarian Z . Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers: A Triple-Blind, Randomized, Placebo-Controlled Trial. Iran J Cancer Prev. 2015; 8(5):e4019. PMC: 4667229. DOI: 10.17795/ijcp-4019. View

12.

Talaat R, El-Sayed W, Agwa H, Gamal-Eldeen A, Moawia S, Zahran M . Anti-inflammatory effect of thalidomide dithiocarbamate and dithioate analogs. Chem Biol Interact. 2015; 238:74-81. DOI: 10.1016/j.cbi.2015.05.017. View

13.

Bantounou M, Plascevic J, Galley H . Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions. Antioxidants (Basel). 2022; 11(3). PMC: 8944604. DOI: 10.3390/antiox11030532. View

14.

Park S, Goldstein D, Krishnan A, Lin C, Friedlander M, Cassidy J . Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2014; 63(6):419-37. DOI: 10.3322/caac.21204. View

15.

Franks M, Macpherson G, Figg W . Thalidomide. Lancet. 2004; 363(9423):1802-11. DOI: 10.1016/S0140-6736(04)16308-3. View

16.

Hamidieh A, Sherafatmand M, Mansouri A, Hadjibabaie M, Ashouri A, Jahangard-Rafsanjani Z . Calcitriol for Oral Mucositis Prevention in Patients With Fanconi Anemia Undergoing Hematopoietic SCT: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Ther. 2015; 23(6):e1700-e1708. DOI: 10.1097/MJT.0000000000000269. View

17.

Garcion E, Sindji L, Leblondel G, Brachet P, DArcy F . 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999; 73(2):859-66. DOI: 10.1046/j.1471-4159.1999.0730859.x. View

18.

Parulekar W, Mackenzie R, Bjarnason G, Jordan R . Scoring oral mucositis. Oral Oncol. 1998; 34(1):63-71. DOI: 10.1016/s1368-8375(97)00065-1. View

19.

Adepu S, Ramakrishna S . Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021; 26(19). PMC: 8512302. DOI: 10.3390/molecules26195905. View

20.

Prasad A . Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009; 12(6):646-52. DOI: 10.1097/MCO.0b013e3283312956. View